Kala Pharmaceuticals to Present at H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, with a pre-recorded fireside chat available from September 12, 2022, at 7:00 a.m. ET. The conference will be held virtually and in New York, NY, and management will be available for one-on-one meetings. Kala focuses on developing therapies for rare eye diseases, including its lead product candidate KPI-012 for persistent corneal epithelial defects, which has received orphan drug designation from the FDA.

ARLINGTON, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye, today announced that it will present at the H.C. Wainwright 24^th Annual Global Investment Conference, being held virtually and in New York, NY. A pre-recorded fireside chat will be made available beginning Monday, September 12, 2022 at 7:00 a.m. ET. Management will also be available for one-on-one meetings throughout the conference.

To access the webcast and subsequent archived recording of the fireside chat, please visit the “Presentations” section of the Kala website at http://kalarx.com.

About Kala Pharmaceuticals, Inc.

Kala is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare diseases of the eye. Kala’s biologics-based investigational therapies utilize Kala’s proprietary Mesenchymal Stem Cell Secretome (MSC-S) platform. Kala’s lead product candidate, KPI-012, is in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, which has received orphan drug designation from the U.S. Food and Drug Administration. Kala is also targeting the potential development of KPI-012 for the treatment of Partial Limbal Stem Cell Deficiency and ocular manifestations of moderate-to-severe Sjögren's and plans to initiate preclinical studies to evaluate the utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on Kala, please visit www.kalarx.com.

Investor Contact:

Hannah Deresiewicz
hannah.deresiewicz@sternir.com
212-362-1200

FAQ

When will Kala Pharmaceuticals present at the H.C. Wainwright Conference?

Kala Pharmaceuticals will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 12, 2022.

What is the focus of Kala Pharmaceuticals?

Kala Pharmaceuticals focuses on developing innovative therapies for rare eye diseases.

What is KPI-012 and its significance for Kala Pharmaceuticals?

KPI-012 is Kala's lead product candidate for treating persistent corneal epithelial defects, which has received orphan drug designation from the FDA.

How can I access Kala Pharmaceuticals' fireside chat?

The fireside chat can be accessed on Kala's website under the 'Presentations' section starting September 12, 2022.

What other conditions is Kala Pharmaceuticals targeting?

Kala is also targeting potential treatments for Partial Limbal Stem Cell Deficiency and ocular manifestations of Sjögren's.